ATE366745T1 - Mutant er-alpha und nachweissysteme für transaktivierung - Google Patents

Mutant er-alpha und nachweissysteme für transaktivierung

Info

Publication number
ATE366745T1
ATE366745T1 AT00981647T AT00981647T ATE366745T1 AT E366745 T1 ATE366745 T1 AT E366745T1 AT 00981647 T AT00981647 T AT 00981647T AT 00981647 T AT00981647 T AT 00981647T AT E366745 T1 ATE366745 T1 AT E366745T1
Authority
AT
Austria
Prior art keywords
eralpha
mutant
test
transactivation
diagnosing
Prior art date
Application number
AT00981647T
Other languages
German (de)
English (en)
Inventor
Koichi Saito
Norihisa Ohe
Hideo Satoh
Original Assignee
Sumitomo Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co filed Critical Sumitomo Chemical Co
Application granted granted Critical
Publication of ATE366745T1 publication Critical patent/ATE366745T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Mushroom Cultivation (AREA)
AT00981647T 1999-12-07 2000-12-01 Mutant er-alpha und nachweissysteme für transaktivierung ATE366745T1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
JP34802299 1999-12-07
JP37066799 1999-12-27
JP2000207011 2000-07-07
JP2000220508 2000-07-21
JP2000234053 2000-08-02
JP2000235463 2000-08-03
JP2000235460 2000-08-03
JP2000235461 2000-08-03

Publications (1)

Publication Number Publication Date
ATE366745T1 true ATE366745T1 (de) 2007-08-15

Family

ID=27573667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00981647T ATE366745T1 (de) 1999-12-07 2000-12-01 Mutant er-alpha und nachweissysteme für transaktivierung

Country Status (8)

Country Link
US (1) US7582476B2 (enExample)
EP (1) EP1237925B1 (enExample)
JP (1) JP4742483B2 (enExample)
AT (1) ATE366745T1 (enExample)
AU (1) AU782142B2 (enExample)
CA (1) CA2393045A1 (enExample)
DE (1) DE60035522T2 (enExample)
WO (1) WO2001042307A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057283A1 (en) * 2001-01-19 2002-07-25 Baylor College Of Medecine Methods and compositions in breast cancer diagnosis and therapeutics
WO2004005497A1 (ja) * 2002-07-02 2004-01-15 Yamanouchi Pharmaceutical Co., Ltd. インスリン抵抗性改善薬スクリーニング方法
EP2977470B1 (en) 2002-10-16 2018-01-03 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
AU2003280793A1 (en) * 2002-11-15 2004-06-15 Sumitomo Chemical Company, Limited MUTANT ESTROGEN RECEPTOR-Alpha AND GENE THEREOF
EP1680447A2 (en) * 2003-10-24 2006-07-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Orthogonal gene switches
FR2863275B1 (fr) * 2003-12-09 2007-08-10 Biomerieux Sa Procede pour le diagnostic/pronostic du cancer du sein
EP1711606A2 (en) 2004-01-20 2006-10-18 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
JP2006153656A (ja) * 2004-11-29 2006-06-15 Olympus Corp 反応カプセル、反応カプセルを使用した検査方法およびシステム
KR20140084232A (ko) 2011-10-25 2014-07-04 아이시스 파마수티컬즈 인코포레이티드 Gccr 발현의 안티센스 조절
MX2015016171A (es) 2013-06-19 2016-08-08 Seragon Pharmaceuticals Inc Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
EA031077B1 (ru) 2013-06-19 2018-11-30 Серагон Фармасьютикалз, Инк. Модулятор рецептора эстрогена и его применения
BR112016020953A2 (pt) * 2014-03-13 2018-01-23 Hoffmann La Roche composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção
CN107531722B (zh) 2015-05-26 2020-07-17 豪夫迈·罗氏有限公司 杂环雌激素受体调节剂及其用途
US10179676B1 (en) 2017-07-26 2019-01-15 William Hagan Taylor Dispenser with self-closing cap

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005049A1 (en) * 1986-02-20 1987-08-27 California Biotechnology Inc. Eucaryotic expression of steroid receptor proteins
FR2634495B1 (fr) * 1988-07-01 1990-10-26 Chambon Pierre Procede de preparation d'une proteine par des levures utilisant un systeme inductible, vecteurs et souches transformees correspondantes
AU8951191A (en) * 1990-10-29 1992-05-26 Dekalb Plant Genetics Isolation of biological materials using magnetic particles

Also Published As

Publication number Publication date
DE60035522D1 (de) 2007-08-23
JP4742483B2 (ja) 2011-08-10
CA2393045A1 (en) 2001-06-14
AU782142B2 (en) 2005-07-07
US20030207380A1 (en) 2003-11-06
AU1886801A (en) 2001-06-18
JP2003516137A (ja) 2003-05-13
DE60035522T2 (de) 2008-03-20
EP1237925A1 (en) 2002-09-11
US7582476B2 (en) 2009-09-01
WO2001042307A1 (en) 2001-06-14
EP1237925B1 (en) 2007-07-11

Similar Documents

Publication Publication Date Title
ATE366745T1 (de) Mutant er-alpha und nachweissysteme für transaktivierung
WO2001042786A3 (en) System for cell based screening : cell spreading
ATE205884T1 (de) Assays und vorrichtungen zum nachweis von extrahepatischer biliäreratresie
GB2383043A (en) Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human brain
DE59405710D1 (de) Mittel zur rauchsimulation für streulichtrauchmelder, verfahren zum abgleich von deren rauchempfindlichkeit und verwendung des mittels
DE60233574D1 (de) Verfahren und zusammensetzungen zum nachweis des aktivierungszustands multipler proteine in einzelzellen
ATE515575T1 (de) Verfahren und sonden für den nachweis von krebs
GB2336684A (en) Predicting logarithmic reduction values
BRPI0410283A (pt) métodos de análise de uma região de ácido nucleico marcadora, de detecção ou monitoração de uma população clonal de células em um mamìfero, de diagnóstico e/ou de monitoração de uma condição de doença de mamìfero e de enriquecimento de uma população de moléculas de ácido nucleico em uma amostra biológica
IL147349A0 (en) Systems and methods for characterizing a biological condition or agent using calibrated gene expression profiles
FI20050011A7 (fi) Menetelmä ja testipakkaus tyypin 2 diabetes mellituksen riskin havaitsemiseksi
WO2005052592A3 (en) Methods for diagnosis, stratification, and monitoring of alzheimer’s disease
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
PT1171873E (pt) Aparelho e metodo para detectar emocoes na voz humana
WO2003013343A3 (en) Method for psychophysiological detection of deception through brain function analysis
WO2004021008A3 (en) Methods for detecting breast and ovarian cancer
WO2004058051A3 (en) Androgen-regulated genes and uses for diagnosis, prognosis and treatment of prostate neoplastic conditions
MXPA01006914A (es) Metodos para identificar combinaciones de entidades como terapeuticas.
WO2001042503A3 (en) Apparatus and methods for drug screening based on nucleic acid analysis
French Proof of efficacy trials: endpoints
DE60038614D1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
Suk et al. Human biomonitoring: research goals and needs.
Schulte Opportunities for the development and use of biomarkers
WO2002037077A3 (en) Screening methods based on transcriptional regulation analysis system using transformed cell lines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties